Penumbra Inc
NYSE:PEN
Penumbra Inc
Free Cash Flow
Penumbra Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Penumbra Inc
NYSE:PEN
|
Free Cash Flow
$147.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
101%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Free Cash Flow
$2.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Free Cash Flow
$2.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Free Cash Flow
$3.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Free Cash Flow
$6.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Free Cash Flow
$586m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
Penumbra Inc
Glance View
In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.
See Also
What is Penumbra Inc's Free Cash Flow?
Free Cash Flow
147.3m
USD
Based on the financial report for Dec 31, 2024, Penumbra Inc's Free Cash Flow amounts to 147.3m USD.
What is Penumbra Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
101%
Over the last year, the Free Cash Flow growth was 79%.
You don't have any saved screeners yet